Acute Multiple Sclerosis Relapse.
OBJECTIVE
This article discusses acute exacerbations (relapses) of multiple sclerosis (MS). Relapses are a hallmark of MS and are often associated with significant functional impairment and decreased quality of life. This review discusses the proposed pathophysiology of MS relapses, triggering factors, associated markers, variants of clinical presentation, and diagnostic recommendations.


RESULTS
Most MS exacerbations are followed by a period of repair leading to clinical remission; however, residual deficits may persist after MS relapse and contribute to the stepwise progression of disability. Treatment of MS relapses is important as it helps to shorten the duration of disability associated with their course. Successful treatment of relapse helps patients with MS obtain a vital sense of being able to gain control over the disease. Patients with relapsing MS who receive treatment report better outcomes than those who are simply observed. This article discusses treatment options for MS relapse, including systemic corticosteroids, adrenocorticotropic hormone, and plasma exchange. Recent findings related to the mechanisms of action of steroids and adrenocorticotropic hormone are also reviewed, and other potential therapies are assessed. A proposed algorithm for MS relapse management is presented, including strategies for steroid-resistant MS exacerbations.


CONCLUSIONS
MS relapses need to be recognized in a timely manner and treated using recommended therapeutic methods.
Regina Radner
RR
Berkovich
D000208:Acute Disease; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000000981:diagnostic imaging* / Q000628:therapy*; D010951:Plasma Exchange / Q000379:methods; D012008:Recurrence; D012307:Risk Factors
D000324:Adrenocorticotropic Hormone; D008775:Methylprednisolone